Simpson Thacher & Bartlett is representing Garda World Security Corporation (“GardaWorld”), Founder, Chairman and CEO Stephan Crétier, and GardaWorld management, while Latham & Watkins acted as...
BC Partners’ Sale of Majority Stake in GardaWorld
Rocket Pharmaceuticals’ $175 Million Public Offering
K&L Gates advised Rocket, and Latham advised underwriters. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced the pricing of an underwritten public offering of 7,812,500 shares of its common...
Acumen’s $130 Million Common Stock Public Offering
Ropes & Gray advised Acumen, and Latham & Watkins advised the underwriters. Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced the pricing of an upsized underwritten public offering of...
Zentalis Pharmaceuticals’ $250 Million Underwritten Offering of Common Stock
Latham & Watkins represented Zentalis in the offering, and Cooley represented the underwriters. Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the pricing of an underwritten offering of...
Amgen’s $24 Billion Senior Notes Offering
Latham & Watkins advised Amgen, and Shearman & Sterling advised the underwriters. Amgen Inc. priced an offering of $24.0 billion aggregate principal amount of senior notes,...
Vor Biopharma’s $115.8 Million Common Stock Offering and Private Placement
Latham & Watkins LLP represented the underwriters and placements agents in the transaction. Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced...
VillageMD’s $8.9 Billion Acquisition of Summit Health-CityMD
Latham & Watkins represented VillageMD in the transaction, Cleary Gottlieb and McDermott Will & Emery represented Summit Health-CityMD, while Wachtell, Lipton, Rosen & Katz served as legal...
Amgen’s $3 Billion Senior Unsecured Notes Offerings
Latham & Watkins represented Amgen in the offerings, while Shearman & Sterling represented represented the underwriters. Amgen Inc. executed a senior unsecured notes offerings consisting of US$1,250,000,000 4.050%...
Zentalis Pharmaceuticals’ $200.2 Million Common Stock Offering
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...
Pfizer’s $25 Million Equity Investment in Zentalis Pharmaceuticals
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological...
Sempra Energy’s $1.25 Billion Notes Offering
Latham & Watkins represented Sempra Energy in the offering. Sempra Energy closed its underwritten offering of US$750,000,000 aggregate principal amount of 3.300% Notes due 2025 and US$500,000,000...
Southern California Gas Company’s $700 Million Notes Offering
Latham & Watkins represented Southern California Gas Company in the offering. Southern California Gas Company, an indirect subsidiary of Sempra Energy, closed on March 14, 2022 its...